The major site of action for obesity treatments based on GLP1R agonists is at the level of the brainstem where neurons share receptors for GLP-1 and GFRAL. Here, authors show two pathways downstream of GFRAL neurons, which are required for the weight-reducing actions of GDF15 and GLP1RA.
- Claire H. Feetham
- Valeria Collabolletta
- Simon M. Luckman